Cited by 247Lung Cancer Treatments and MutationsBrain Metastases and TreatmentLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials

Open access

Goss, G., Tsai, C.-M., Shepherd, F.A., Ahn, M.-J., Bazhenova, L., Crinò, L., de Marinis, F., Felip, E., Morabito, A., Hodge, R., Cantarini, M., Johnson, M., Mitsudomi, T., Jänne, P.A., Yang, J.C.-H.·2018·Annals of Oncology

DOI 10.1093/annonc/mdx820

Open this paper in CoChat — free account

Abstract

Background: Central nervous system (CNS) metastases are common in patients with non-small-cell lung cancer (NSCLC). Osimertinib has shown systemic efficacy in patients with CNS metastases, and early clinical evidence shows efficacy in the CNS. To evaluate osimertinib activity further, we present a pre-specified subgroup analysis of CNS response using pooled data from two phase II studies: AURA extension (NCT01802632) and AURA2 (NCT02094261). Patients and methods: Patients with T790M-positive advanced NSCLC, who had progressed following prior epidermal growth factor receptor-tyrosine kinase inhibitor treatment, received osimertinib 80 mg od (n = 411). Patients with stable, asymptomatic CNS metastases were eligible for enrolment; prior CNS treatment was allowed. Patients with ≥1 measurable CNS lesion (per RECIST 1.1) on baseline brain scan by blinded independent central neuroradiology review (BICR) were included in the evaluable for CNS response set (cEFR). The primary outcome for this CNS analysis was CNS objective response rate (ORR) by BICR; secondary outcomes included CNS duration of response, disease control rate (DCR) and progression-free survival (PFS). Results: Of 128 patients with CNS metastases on baseline brain scans, 50 were included in the cEFR. Confirmed CNS ORR and DCR were 54% [27/50; 95% confidence interval (CI) 39-68] and 92% (46/50; 95% CI 81-98), respectively. CNS response was observed regardless of prior radiotherapy to the brain. Median CNS duration of response (22% maturity) was not reached (range, 1-15 months); at 9 months, 75% (95% CI 53-88) of patients were estimated to remain in response. Median follow-up for CNS PFS was 11 months; median CNS PFS was not reached (95% CI, 7, not calculable). The safety profile observed in the cEFR was consistent with the overall patient population. Conclusions: Osimertinib demonstrated clinically meaningful efficacy against CNS metastases, with a high DCR, encouraging ORR, and safety profile consistent with that reported previously. ClinicalTrials.gov number: NCT01802632; NCT02094261.

Integrity signals

Registry

Crossref · 10.1093/annonc/mdx820

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Self-citation
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379
Self-citation
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Cross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0337 · Cited by 2,246
Self-citation
Comparisons between the National Comprehensive Cancer Network (NCCN) non-small-cell lung cancer (NSCLC) Clinical Practice Guidelines (Chinese version), the NCCN original edition, and the European Society for Medical Oncology NSCLC Guidelines in 2009
Xu, Y., Liu, H., Chen, J., & Zhou, Q. (2010) · Thoracic Cancer · doi:10.1111/j.1759-7714.2010.00016.x · Cited by 884
Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial
Mulvenna, P., Nankivell, M. G., Barton, R., Finn, C. F., Wilson, P., McColl, E., MOORE, B. J., Brisbane, I., Ardron, D., Holt, T., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30825-x · Cited by 723
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
Goss, G. D., Tsai, C., Shepherd, F. A., Bazhenova, L. A., Lee, J. S., Chang, G., Crinò, L., Satouchi, M., Chu, Q. S.-C., Hida, T., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30508-3 · Cited by 654
Self-citation
Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component
Yang, J. C.-H., Ahn, M.-J., Kim, D.-W., Ramalingam, S. S., Sequist, L. V., Su, W.-C., Kim, S.-W., Kim, J.-H., Planchard, D., Felip, E., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.3223 · Cited by 571
Self-citation
Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers
Rangachari, D., Yamaguchi, N., VanderLaan, P. A., Folch, E. E., Mahadevan, A., Floyd, S., Uhlmann, E. J., Wong, E. T., Dahlberg, S. E., Huberman, M. S., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.01.020 · Cited by 547
Neurocognitive Function of Patients with Brain Metastasis Who Received Either Whole Brain Radiotherapy Plus Stereotactic Radiosurgery or Radiosurgery Alone
Aoyama, H., Tago, M., Kato, N., Toyoda, T., Kenjyo, M., Hirota, S., Shioura, H., Inomata, T., Kunieda, E., Hayakawa, K., et al. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.03.048 · Cited by 542

Show all 27 references

Research works printed but not linked: 1

Yang, 2017, Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study Phase II extension component, J Clin Oncol, 35, 1288, 10.1200/JCO.2016.70.3223 · DOI · Paper page

Sorted by citations

Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline
Vogelbaum, M. A., Brown, P. D., Messersmith, H. J., Brastianos, P. K., Burri, S. H., Cahill, D. P., Dunn, I. F., Gaspar, L. E., Gatson, N. T., Gondi, V., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.02314 · Cited by 878
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Reungwetwattana, T., Nakagawa, K., Cho, B. C., Cobo, M., Cho, E. K., Bertolini, A., Bohnet, S., Zhou, C., Lee, K. H., Nogami, N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.3118 · Cited by 811
Self-citation
The emerging treatment landscape of targeted therapy in non-small-cell lung cancer
Yuan, M., Huang, L., Chen, J., Wu, J., & Xu, Q. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0099-9 · Cited by 696
Overcoming therapy resistance in EGFR-mutant lung cancer
Passaro, A., Jänne, P. A., Mok, T., & Peters, S. (2021) · Nature Cancer · doi:10.1038/s43018-021-00195-8 · Cited by 565
CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)
Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Han, J.-Y., Katakami, N., Kim, H. R., Hodge, R., Kaur, P., Brown, A. P., Ghiorghiu, D., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.9363 · Cited by 517
Self-citation
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396
Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study
Yang, J. C. H., Kim, S.-W., Kim, D.-W., Lee, J.-S., Cho, B. C., Ahn, J.-S., Lee, D. H., Kim, T. M., Goldman, J. W., Natale, R. B., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.00457 · Cited by 395
Self-citation
Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)
Cho, J. H., Lim, S. H., An, H. J., Kim, K. H., Park, K. U., Kang, E. J., Choi, Y. H., Ahn, M. S., Lee, M. H., Sun, J.-M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.00931 · Cited by 358
Self-citation
Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
Recondo, G., Facchinetti, F., Olaussen, K. A., Besse, B., & Friboulet, L. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0081-4 · Cited by 321
Third generation EGFR TKIs: current data and future directions
Tan, C., Kumarakulasinghe, N. B., Huang, Y., Ang, Y. L. E., Choo, J. R.-E., Goh, B.-C., & Soo, R. A. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0778-0 · Cited by 322
Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
Chmielecki, J., Gray, J. E., Cheng, Y., Ohe, Y., Imamura, F., Cho, B. C., Lin, M., Majem, M., Shah, R. N. H., Rukazenkov, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-35961-y · Cited by 298
Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)
Gelatti, A., Drilon, A. E. D. C., & Santini, F. C. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.09.017 · Cited by 220
Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC
Nagasaka, M., Zhu, V. W., Lim, S. M., Greco, M., Wu, F., & Ou, S.-H. I. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.11.028 · Cited by 219
Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions
Aizer, A. A., Lamba, N., Ahluwalia, M. S., Aldape, K., Boire, A. A., Brastianos, P. K., Brown, P. D., Camidge, D. R., Chiang, V., Davies, M. A., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac118 · Cited by 217
A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy
Park, S., Lee, M.-H., Seong, M., Kim, S. T., Kang, J. H., Cho, B. C., Lee, K. H., Cho, E. K., Sun, J., Lee, S.-H., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.06.017 · Cited by 184
Self-citation
Management of Brain Metastases in Non–Small-Cell Lung Cancer
Ernani, V., & Stinchcombe, T. E. (2019) · Journal of Oncology Practice · doi:10.1200/jop.19.00357 · Cited by 189
Osimertinib in patients with T790M mutation‐positive, advanced non–small cell lung cancer: Long‐term follow‐up from a pooled analysis of 2 phase 2 studies
Ahn, M., Tsai, C., Shepherd, F. A., Bazhenova, L. A., Sequist, L. V. D., Hida, T., Yang, J. C., Ramalingam, S. S., Mitsudomi, T., Janne, P. A., et al. (2018) · Cancer · doi:10.1002/cncr.31891 · Cited by 168
Self-citation
Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial
Lü, S., Wang, Q., Zhang, G., Dong, X., Yang, C., Song, Y., Chang, G., Lü, Y., Pan, H., Chiu, C., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.10.024 · Cited by 149
Self-citation
CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor–Mutated Advanced Non–Small-Cell Lung Cancer
Janne, P. A., Planchard, D., Kobayashi, K., Cheng, Y., Lee, C. K., Valdiviezo, N., Лактионов, К. К., Yang, T., Yu, Y., Kato, T., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.02219 · Cited by 147
Self-citation
Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial
Subbiah, V., Gainor, J. F., Oxnard, G. R., Tan, D. S.-W., Owen, D. H., Cho, B. C., Loong, H. H.-F., McCoach, C. E., Weiss, J. M., Kim, Y. J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0800 · Cited by 141
Self-citation
Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non–Small Cell Lung Cancer
Sabari, J. K., Velcheti, V., Shimizu, K., Strickland, M. R., Heist, R. S., Singh, M., Nayyar, N., Giobbie‐Hurder, A., Digumarthy, S. R., Gainor, J. F., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0383 · Cited by 138
Systemic treatment of brain metastases in non-small cell lung cancer
Page, S., Milner-Watts, C., Perna, M., Janžič, U., Vidal, N., Kaudeer, N., Ahmed, M., McDonald, F., Locke, I., Minchom, A. R., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.03.006 · Cited by 121
Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation
Shi, Y., Zhang, S., Hu, X., Feng, J., Ma, Z., Zhou, J., Yang, N., Wu, L., Liao, W., Zhong, D., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.010 · Cited by 111
ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection
Wu, Y.-L. L. C., Herbst, R. S., Mann, H., Rukazenkov, Y., Marotti, M., & Tsuboi, M. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.04.004 · Cited by 110
Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study
Hochmair, M. J., Morabito, A., Hao, D., Yang, C., Soo, R. A., Yang, J. C., Gucalp, R. A., Halmos, B., Wang, L., Golembesky, A., et al. (2018) · Future Oncology · doi:10.2217/fon-2018-0711 · Cited by 99
Self-citation
Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
Santarpía, M., Liguori, A., Karachaliou, N., González‐Cao, M., Daffinà, M. G., D’Aveni, A., Marabello, G., Altavilla, G., & Rosell, R. (2017) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s119644 · Cited by 104
Mechanisms of resistance to osimertinib
Lazzari, C., Gregorc, V., Karachaliou, N., Rosell, R., & Santarpía, M. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.08.30 · Cited by 96
Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
Wright, N. A., & Goss, G. D. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.06.01 · Cited by 95
Self-citation
Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer
Kelly, W., Shah, N. J., & Subramaniam, D. S. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00208 · Cited by 86
Mechanisms of EGFR Resistance in Glioblastoma
Pan, P., & Magge, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228471 · Cited by 88
Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment
Remón, J., & Besse, B. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00088 · Cited by 80
Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes
John, T., Taylor, A., Wang, H., Eichinger, C. S., Freeman, C. S., & Ahn, M. (2021) · Cancer Epidemiology · doi:10.1016/j.canep.2021.102080 · Cited by 80
Self-citation
A Phase II Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis From NSCLC: Results for the T790M Cohort of the OCEAN Study (LOGIK1603/WJOG9116L)
Yamaguchi, H., Wakuda, K., Fukuda, M., Kenmotsu, H., Mukae, H., Ito, K., Chibana, K., Inoue, K., Miura, S., Tanaka, K., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.07.026 · Cited by 71
The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib
Vishwanathan, K., Dickinson, P. A., So, K., Thomas, K., Chen, Y., de Castro, J., Dingemans, A. C., Kim, H. R., Kim, J.-H., Krebs, M., et al. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13534 · Cited by 75
Self-citation
Epidermal Growth Factor Receptor Inhibitors in Glioblastoma: Current Status and Future Possibilities
Ezzati, S., Salib, S., Balasubramaniam, M., & Aboud, O. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042316 · Cited by 71
Recent advances in gold and silver nanoparticle based therapies for lung and breast cancers
Malik, P., & Mukherjee, T. K. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.10.048 · Cited by 70
High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial
Zwierenga, F., van Veggel, B. A. M. H., Hendriks, L. E. L., Hiltermann, T. J. N., Hiddinga, B. I., Hijmering-Kappelle, L. B. M., ter Elst, A., Hashemi, S. M. S., Dingemans, A. C., van der Leest, C., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.06.012 · Cited by 70
FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation
Odogwu, L., Mathieu, L. N., Goldberg, K. B., Blumenthal, G. M., Larkins, E. A., Fiero, M. H., Rodríguez, L., Bijwaard, K. E., Lee, E. Y., Philip, R., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0425 · Cited by 68
A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2
Park, C., Cho, H.-J., Choi, Y. D., Oh, I., & Kim, Y. (2018) · Cancer Research and Treatment · doi:10.4143/crt.2018.387 · Cited by 65
Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities
Yoda, S., Dagogo‐Jack, I., & Hata, A. N. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.08.007 · Cited by 68
Outcome and prognostic factors following palliative craniospinal irradiation for leptomeningeal carcinomatosis
Shafie, R. A. E., Böhm, K., Weber, D., Lang, K., Schlaich, F., Adeberg, S., Paul, A., Haefner, M. F., Katayama, S., Sterzing, F., et al. (2019) · Cancer Management and Research · doi:10.2147/cmar.s182154 · Cited by 61
Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer
Chu, C., Choi, J. N., Eaby‐Sandy, B., Langer, C. J., & Lacouture, M. E. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0582 · Cited by 58
Brain Metastases in Non-Small-Cell Lung Cancer: Are Tyrosine Kinase Inhibitors and Checkpoint Inhibitors Now Viable Options?
Abdallah, S. M.-B., & Wong, A. N. M. (2018) · Current Oncology · doi:10.3747/co.25.3733 · Cited by 57
Combination of radiotherapy and immunotherapy for brain metastases: A systematic review and meta-analysis
Petrelli, F., Stefani, A. D., Trevisan, F., Parati, M. C., Inno, A., Merelli, B., Ghidini, M., Bruschieri, L., Vitali, E., Cabiddu, M., et al. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.102830 · Cited by 59
EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer
John, T., Akamatsu, H., Delmonte, A., Su, W., Lee, J. S., Chang, G., Huang, X., Jenkins, S. C., & Wu, Y.-L. L. C. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.10.027 · Cited by 55
Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease
Hochmair, M. J. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0566-1 · Cited by 55
Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR -mutant glioblastoma
Makhlin, I., Salinas, R. D., Zhang, D., Jacob, F., Ming, G.-L., Song, H., Saxena, D., Dorsey, J. F., Nasrallah, M. P., Morrissette, J. J. D., et al. (2019) · CNS Oncology · doi:10.2217/cns-2019-0014 · Cited by 55
A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group
written on behalf of the AME Lung Cancer Collaborative Group, Jiang, T., Su, C., Ren, S., Cappuzzo, F., Rocco, G., Palmer, J. D., van Zandwijk, N., Blackhall, F. H., Le, X., et al. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.07.61 · Cited by 53
Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study
Schmid, S., Klingbiel, D., Aeppli, S., Britschgi, C., Gautschi, O. P., Pless, M., Rothschild, S. I., Wannesson, L., Janthur, W.-D., Förbs, D., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.02.020 · Cited by 54
Update on the Management of Brain Metastasis
Singh, K., Saxena, S., Khosla, A. A., McDermott, M. W., Kotecha, R. R., & Ahluwalia, M. S. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01312-w · Cited by 56
Osimertinib for EGFR -Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study
Xie, L., Nagpal, S., Wakelee, H. A., Li, G., Soltys, S. G., & Neal, J. W. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0264 · Cited by 49
Brain Distribution of a Panel of Epidermal Growth Factor Receptor Inhibitors Using Cassette Dosing in Wild-Type and Abcb1/Abcg2-Deficient Mice
Kim, M., Laramy, J. K., Mohammad, A. S., Talele, S., Fisher, J. E., Sarkaria, J. N., & Elmquist, W. F. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.084210 · Cited by 49
Pattern of Recurrence Analysis in Metastatic EGFR-Mutant NSCLC Treated with Osimertinib: Implications for Consolidative Stereotactic Body Radiation Therapy
Guo, T., Ni, J., Yang, X., Li, Y., Li, Y., Zou, L., Wang, S., Liu, Q., Chu, L., Chu, X., et al. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2019.12.042 · Cited by 50
Management of brain metastasized non-small cell lung cancer (NSCLC) – From local treatment to new systemic therapies
Tsakonas, G., Petris, L. D., & Ekman, S. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.02.004 · Cited by 48
Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors
Wrona, A., Dziadziuszko, R., & Jassem, J. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.10.011 · Cited by 48
Assessment of Effectiveness and Safety of Osimertinib for Patients With Intracranial Metastatic Disease
Erickson, A. W., Brastianos, P. K., & Das, S. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.1617 · Cited by 46
Treatment options for EGFR mutant NSCLC with CNS involvement—Can patients BLOOM with the use of next generation EGFR TKIs?
Tan, C., Cho, B. C., & Soo, R. A. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.02.012 · Cited by 45
Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction
Kunimasa, K., Oka, T., Hara, S., Yamada, N., Oizumi, S., Miyashita, Y., Kamada, R., Funamoto, T., Kawachi, H., Kawamura, T., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.10.021 · Cited by 44
Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors
Saboundji, K., Auliac, J. B., Pérol, M., François, G., Janicot, H., Marcq, M., Dubos‐Arvis, C., Renault, A., Guisier, F., Odier, L., et al. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0581-2 · Cited by 41
Osimertinib
Malapelle, U., Ricciuti, B., Baglivo, S., Pepe, F., Pisapia, P., Anastasi, P., Tazza, M., Sidoni, A., Liberati, A. M., Bellezza, G., et al. (2018) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-91442-8_18 · Cited by 44
Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies
Popat, S., Ahn, M., Ekman, S., Leighl, N. B., Ramalingam, S. S., Reungwetwattana, T., Siva, S., Tsuboi, M., Wu, Y.-L. L. C., & Yang, J. C. (2023) · Targeted Oncology · doi:10.1007/s11523-022-00941-7 · Cited by 39
Self-citation
Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy
Ricciuti, B., Baglivo, S., Paglialunga, L., Giglio, A. D., Bellezza, G., Chiari, R., Crinò, L., & Metro, G. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017702820 · Cited by 39
Self-citation
Brexpiprazole, a Serotonin-Dopamine Activity Modulator, Can Sensitize Glioma Stem Cells to Osimertinib, a Third-Generation EGFR-TKI, via Survivin Reduction
Suzuki, S., Yamamoto, M., Sanomachi, T., Togashi, K., Sugai, A., Seino, S., Yoshioka, T., Kitanaka, C., & Okada, M. (2019) · Cancers · doi:10.3390/cancers11070947 · Cited by 36
Targeting positive feedback between BASP1 and EGFR as a therapeutic strategy for lung cancer progression
Lin, C., Huang, Y., Cho, C.-F., Lin, Y., Lo, C.-C., Kuo, T.-T., Tseng, G., Cheng, W., Chang, W., Hsiao, T., et al. (2020) · Theranostics · doi:10.7150/thno.49425 · Cited by 38
Advances in the Molecular Landscape of Lung Cancer Brain Metastasis
Souza, V. G. P., de Araújo, R. P., Santesso, M. R., Seneda, A. L., Minutentag, I. W., Felix, T. F., Filho, P. T. H., Pewarchuk, M. E., Brockley, L. J., Marchi, F. A., et al. (2023) · Cancers · doi:10.3390/cancers15030722 · Cited by 42
Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience
Ricciuti, B., Baglivo, S., Giglio, A. D., & Chiari, R. (2018) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466618808659 · Cited by 39
Biomarkers of Osimertinib Response in Patients with Refractory, EGFR-T790M–positive Non–Small Cell Lung Cancer and Central Nervous System Metastases: The APOLLO Study
Xing, L., Pan, Y., Shi, Y., Shu, Y., Feng, J., Li, W., Cao, L., Wang, L., Gu, W., Song, Y., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2081 · Cited by 37
Advances in clinical trials of targeted therapy and immunotherapy of lung cancer in 2018
Hu, Z., Li, M., Chen, Z., Zhan, C., Lin, Z., & Wang, Q. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.10.17 · Cited by 36
Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials
Zhao, P., Zhen, H., Zhao, H., Zhao, L., & Cao, B. (2022) · BMC Cancer · doi:10.1186/s12885-022-09444-0 · Cited by 36
Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b Study
Shi, Y., Li, B., Wu, L., Pan, Y., Pan, Z., Liu, Y., Fan, Y., Ji, Y., Fang, J., Shi, Q., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.05.011 · Cited by 35
Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834
Miura, S., Tanaka, H., Misumi, T., Yoshioka, H., Tokito, T., Fukuhara, T., Sato, Y., Shiraishi, Y., Naoki, K., Akamatsu, H., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02007 · Cited by 37
The effectiveness of afatinib and osimertinib in a Chinese patient with advanced lung adenocarcinoma harboring a rare triple EGFR mutation (R670W/H835L/L833V): a case report and literature review
Qin, B., Jiao, X., Yuan, L., Liu, K., Wang, Z., Qin, W., & Zang, Y. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s167346 · Cited by 33
Hype or hope – Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC?
Papini, F., Sundaresan, J., Leonetti, A., Tiseo, M., Rolfo, C. D., Peters, G. J., & Giovannetti, E. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103454 · Cited by 35
Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b Study
Shi, Y., Wu, S., Wang, K., Cang, S., Yao, W., Fan, Y., Wu, L., Huang, M., Li, X., Pan, Y., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.08.015 · Cited by 33
Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study
Lü, S., Ahn, M.-J., Reungwetwattana, T., Özgüroğlu, M., Kato, T., Yang, J. C., Huang, M., Fujiki, F., Inoue, T., Quang, L.-V., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.08.2243 · Cited by 32
Self-citation
Emerging Systemic Treatment Perspectives on Brain Metastases: Moving Toward a Better Outlook for Patients
Alvarez-Breckenridge, C. A., Remón, J., Piña, Y., Nieblas‐Bedolla, E., Forsyth, P. A., Hendriks, L. E. L., & Brastianos, P. K. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_352320 · Cited by 32
Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer
Dagogo‐Jack, I., Azzolli, C. G., Fintelmann, F. J., Mino-Kenudson, M. A., Farago, A. F., Gainor, J. F., Jiang, G. Y., Piotrowska, Z., Heist, R. S., Lennes, I. T., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00299 · Cited by 33
Central nervous system activity of first-line osimertinib in epidermal growth factor receptor-mutant advanced non-small cell lung cancer
Liam, C. K. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2018.12.68 · Cited by 31
Brain metastases in patients with oncogenic-driven non-small cell lung cancer: Pros and cons for early radiotherapy
Lee, J., & Ahn, M. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102291 · Cited by 31
Self-citation
Management of Brain Metastases
Collier, E. F., Chiang, V., & Goldberg, S. B. (2021) · Current cancer research · doi:10.1007/978-3-030-74028-3_6 · Cited by 32
Efficacy and safety of therapies for EGFR-mutant non-small cell lung cancer with brain metastasis: an evidence-based Bayesian network pooled study of multivariable survival analyses
Zhao, B., Wang, Y., Wang, Y., Chen, W., Zhou, L., Liu, P. H., Kong, Z., Dai, C., Wang, Y., & Ma, W. (2020) · Aging · doi:10.18632/aging.103455 · Cited by 30
Therapeutic approaches for T790M mutation positive non-small-cell lung cancer
Attili, I., Karachaliou, N., Conte, P., Bonanno, L., & Rosell, R. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1508347 · Cited by 32
Strategies to Preserve Cognition in Patients With Brain Metastases: A Review
Robin, T. P., & Rusthoven, C. G. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00415 · Cited by 31
Safety of osimertinib in EGFR -mutated non-small cell lung cancer
Mezquita, L., Varga, A., & Planchard, D. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1549222 · Cited by 31
Brain Metastasis Treatment: The Place of Tyrosine Kinase Inhibitors and How to Facilitate Their Diffusion across the Blood–Brain Barrier
Angeli, E., & Bousquet, G. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091446 · Cited by 30
Lazertinib in EGFR-Variant Non–Small Cell Lung Cancer With CNS Failure to Prior EGFR Tyrosine Kinase Inhibitors
Hong, M. H., Choi, Y. J., Ahn, H. K., Lim, S. M., Keam, B., Kim, D., Kim, T. M., Youk, J., Kim, Y. J., Hwang, S., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.2640 · Cited by 27
The impact of EGFR-TKI use on clinical outcomes of lung adenocarcinoma patients with brain metastases after Gamma Knife radiosurgery: a propensity score-matched analysis based on extended JLGK0901 dataset (JLGK0901-EGFR-TKI)
Yomo, S., Serizawa, T., Yamamoto, M., Higuchi, Y., Sato, Y., Shuto, T., Akabane, A., Jokura, H., Kawagishi, J., & Aoyama, H. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03282-0 · Cited by 26
Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study
Lü, S., Zhang, Y., Zhang, G., Zhou, J., Cang, S., Cheng, Y., Wu, G., Cao, P., Lv, D., Jian, H., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.06.002 · Cited by 27
Self-citation
Impacts of EGFR-mutation status and EGFR-TKI on the efficacy of stereotactic radiosurgery for brain metastases from non-small cell lung adenocarcinoma: A retrospective analysis of 133 consecutive patients
Yomo, S., & Oda, K. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.03.013 · Cited by 28
Comparative effectiveness of multi-fraction stereotactic radiosurgery for surgically resected or intact large brain metastases from non-small-cell lung cancer (NSCLC)
Minniti, G. C., Scaringi, C., Lanzetta, G., Anzellini, D., Bianciardi, F., Tolu, B., Morace, R., Romano, A., Osti, M. F., Gentile, P., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.04.021 · Cited by 26
Non-Small-Cell Lung Cancer: New Rare Targets—New Targeted Therapies—State of The Art and Future Directions
Stencel, K. M., Chmielewska, I., Milanowski, J., & Ramlau, R. (2021) · Cancers · doi:10.3390/cancers13081829 · Cited by 27
Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study
Peled, N., Kian, W., Inbar, E., Goldstein, I. M., Zemel, M., Rotem, O., Rozenblum, A. B., Nechushtan, H., Dudnik, E., Levin, D., et al. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab188 · Cited by 27
Leveraging Molecular and Immune-Based Therapies in Leptomeningeal Metastases
Wilcox, J. A., & Boire, A. A. (2022) · CNS Drugs · doi:10.1007/s40263-022-00975-5 · Cited by 25
Challenges and Novel Opportunities of Radiation Therapy for Brain Metastases in Non-Small Cell Lung Cancer
Jablonska, P. A., Bosch‐Barrera, J., Serrano, D., Valiente, M., Calvo, A., & Aristu, J. (2021) · Cancers · doi:10.3390/cancers13092141 · Cited by 24
Systemic Therapy for Lung Cancer Brain Metastases
Pellerino, A., Bruno, F., Rudà, R., & Soffietti, R. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00911-7 · Cited by 26
Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies
Hu, X., Zhang, S., Ma, Z., Feng, J., Wu, L., Lv, D., Zhou, J., Zhang, X., Liu, L., Yu, Q., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-02865-z · Cited by 26
Osimertinib in untreated epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer
Gregorc, V., Lazzar, C., Karachaliou, N., Rosell, R., & Santarpía, M. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.03.19 · Cited by 23
Resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer
Steen, N. V. D., Giovannetti, E., Carbone, D., Leonetti, A., Rolfo, C. D., & Peters, G. J. (2018) · Cancer Drug Resistance · doi:10.20517/cdr.2018.13 · Cited by 23
Pharmacokinetic Study of Osimertinib in Cancer Patients with Mild or Moderate Hepatic Impairment
Grande, E., Harvey, R. D., You, B., Batlle, J. F., Galbraith, H., Sarantopoulos, J., Ramalingam, S. S., Mann, H., So, K., Johnson, M. G., et al. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.255919 · Cited by 24
Self-citation
Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors
Lee, J., Chen, H., Hsu, F., Chen, J., Liao, W., Shih, J., Yu, C., Chen, K., Tsai, T.-H., & Yang, J. C. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0152 · Cited by 24
Self-citation

Authors: Goss, G., Tsai, C.-M., Shepherd, F. A., Ahn, M.-J., Bazhenova, L., Crinò, L., de Marinis, F., Felip, E., Morabito, A., Hodge, R., Cantarini, M., Johnson, M., Mitsudomi, T., Jänne, P. A., & Yang, J. C.-H.
Affiliations: University of Ottawa (CA)
Taipei Veterans General Hospital (TW)
University Health Network (CA)
Samsung Medical Center (KR)
Moores Cancer Center (US)
Azienda Ospedaliera di Perugia (IT)
Vall d'Hebron Institute of Oncology (ES)
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
AstraZeneca (United Kingdom) (GB)
Kindai University (JP)
National Taiwan University Hospital (TW)
Corresponding author: Goss, G.
ORCID: Goss, G.
Tsai, C.-M.
Shepherd, F.A.
Ahn, M.-J.
Bazhenova, L.
Crinò, L.
Felip, E.
Morabito, A.
Hodge, R.
Cantarini, M.
Johnson, M.
Mitsudomi, T.
Yang, J.C.-H.
Venue: Annals of Oncology
Publisher: Elsevier BV
Published: 2018-03
Volume: 29
Issue: 3
Pages: 687-693
ISSN: 0923-7534 (ISSN-L)
DOI: 10.1093/annonc/mdx820
OpenAlex: W2776194348
Cited by: 247
References: 27
Citations by year: 2026: 5 · 2025: 12 · 2024: 17 · 2023: 32 · 2022: 25 · 2021: 35 · 2020: 30 · 2019: 40 · 2018: 45
FWCI: 27.37
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-nd
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 613 d)
Locations: Annals of Oncology (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › Brain Metastases and Treatment
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: osimertinib, central nervous system metastasis, disease control rate, progression-free survival, EGFR tyrosine kinase inhibitors, brain metastases, EGFR mutation, targeted therapy, safety profile, subgroup analysis
MeSH terms: Progression-Free Survival, Acrylamides, Adult, Aged, Aniline Compounds, Antineoplastic Agents, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Female, Humans, Indoles, Lung Neoplasms, Male, Middle Aged, Piperazines, Pyrimidines, Central Nervous System Neoplasms, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks